Shigella dysenteriae serotype 1 in west Africa: Intervention strategy for an outbreak in Sierra Leone

Lancet

Volumn 362, Issue 9385, 2003, Pages 705-706

  Guerin, Philippe J ^a,b   Brasher, Christopher ^c   Baron, Emmanuel ^c   Mic, Daniel ^c   Grimont, Francine ^d   Ryan, Mike ^e   Aavitsland, Preben ^a   Legros, Dominique ^b  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b EPICENTRE   (France)

^c MÉDECINS SANS FRONTIÈRES   (Switzerland)

^d INSTITUT PASTEUR   (France)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFIXIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; NALIDIXIC ACID; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE;

AFRICA; ANTIBIOTIC SENSITIVITY; ARTICLE; CHILD; CLINICAL FEATURE; DIARRHEA; DISEASE SEVERITY; DRUG COST; DRUG EFFECT; DRUG SAFETY; DRUG SENSITIVITY; FATALITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SEROLOGY; SHIGELLA DYSENTERIAE; SHIGELLOSIS; SIERRA LEONE;

EID: 0042329255     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14227-4     Document Type: Article

References (5)

1. Keusch G.T., Bennish M.L. Shigellosis. Bacterial infections of humans: epidemiology and control. 1998;631-656 Plenum Medical Book Company, New York and London.
2. Legros D., Paquet C., Dorlencourt F., Saoult E. Risk factors for death in hospitalized dysentery patients in Rwanda. Trop Med Int Health. 4:1999;428-432.
3. Ries A.A., Wells J.G., Olivola D., et al. Epidemic Shigella dysenteriae type 1 in Burundi: panresistance and implications for prevention. J Infect Dis. 169:1994;1035-1041.
4. Hooper D.C. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis. 31:(suppl):2000;S24-S28.
5. Bethell D.B., Hien T.T., Phi L.T., et al. Effects on growth of single short courses of fluoroquinolones. Arch Dis Child. 74:1996;44-46.